Hagens Berman files securities class action against PROCEPT BioRobotics

By Atlas Watchline Staff · Legal · September 1, 2026

Hagens Berman says it filed a securities class action claiming PROCEPT BioRobotics misled investors about handpiece sales, inventory and discounts.

Hagens Berman says it filed a securities class action claiming PROCEPT BioRobotics misled investors about handpiece sales, inventory and discounts.

Hagens Berman Sobol Shapiro LLP said on Sept. 1 that it filed a securities class action against PROCEPT BioRobotics Corp., alleging the company misled investors about demand for its single-use handpiece used in Aquablation therapy.

The firm said the case involves investors who bought or otherwise acquired PROCEPT common stock between Feb. 28, 2024, and Feb. 25, 2026. It said the lead plaintiff deadline is Sept. 22, 2026.

According to the release, the lawsuit centers on communications about handpiece sales, inventory levels and discounting. Hagens Berman alleges PROCEPT used a discount program to encourage customers to place bulk orders above their procedure demand, which it says pulled sales forward from later periods and inflated reported unit sales and revenue.

The release points to several disclosure dates it says affected the stock. It says PROCEPT reported second-quarter 2025 results on Aug. 6, 2025, and that handpiece sales deteriorated and missed consensus estimates. It says the company again missed expected handpiece unit sales on Nov. 4, 2025, when management discussed optimizing field inventory and said it had not been managing customer inventory.

The release says PROCEPT’s Feb. 25, 2026 results were the first time the company disclosed the number of procedures in the field. It says the company also said U.S. handpiece sales had exceeded procedures in each quarter since the first quarter of 2023, that cumulative excess customer inventory topped 10,000 units, and that U.S. handpiece sales fell 30% sequentially. The release says PROCEPT also said it was ending a previously undisclosed bulk-order discount program used to drive large purchases in the final weeks of each quarter.

Hagens Berman also said PROCEPT shares had fallen $22.06, or more than 48%, by Feb. 25, 2026, from the close on Aug. 6, 2025, according to the release.

Reed Kathrein, a partner at Hagens Berman, said the firm is examining whether PROCEPT intentionally pulled in future-quarter sales to make it appear the company was meeting expectations and whether its investor communications were transparent.

The release does not include a response from PROCEPT to the allegations. The case now moves toward the Sept. 22 lead plaintiff deadline noted in the notice.

Sources

• PR Newswire release from Hagens Berman Sobol Shapiro LLP

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.